Combined anti-platelet therapy with aspirin and clopidogrel: Risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?

Journal of the Neurological Sciences

Volumn 284, Issue 1-2, 2009, Pages 155-157

  Hermann, Andreas ^a,b   Dzialowski, Imanuel ^a   Koch, Roland ^a   Gahn, Georg ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Antiplatelets; Intracerebral hemorrhage; Ischemic stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; CLOPIDOGREL;

ADULT; AGED; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; THROMBOPHILIA; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 67849130410     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.05.003     Document Type: Article

References (11)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333(24):1581-7.
2. Lansberg M.G., Thijs V.N., Bammer R., Kemp S., Wijman C.A., Marks M.P., et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 38 8 (2007) 2275-2278
3. Tanne D., Kasner S.E., Demchuk A.M., Koren-Morag N., Hanson S., Grond M., et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 105 14 (2002) 1679-1685
4. Uyttenboogaart M., Koch M.W., Koopman K., Vroomen P.C., De Keyser J., and Luijckx G.J. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol 65 5 (2008) 607-611
5. Wahlgren N., Ahmed N., Eriksson N., Aichner F., Bluhmki E., Davalos A., et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 39 12 (2008) 3316-3322
6. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 9431 (2004) 331-337
7. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of Clopidogrel Added toAspirin in Patients with Atrial Fibrillation. N Engl J Med 2009;360(20):2127-9.
8. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 16 (2006) 1706-1717
9. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 9526 (2006) 1903-1912
10. Usman M.H., Notaro L.A., Nagarakanti R., Brahin E., Dessain S., Gracely E., et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?. Am J Cardiol 103 8 (2009) 1107-1112
11. Pessin M.S., Teal P.A., and Caplan L.R. Hemorrhagic infarction: guilt by association?. AJNR Am J Neuroradiol 12 6 (1991) 1123-1126